Provided by Tiger Trade Technology Pte. Ltd.

PharmaCyte Biotech, Inc.

0.7090
+0.00420.60%
Volume:37.77K
Turnover:26.80K
Market Cap:7.19M
PE:-0.64
High:0.7500
Open:0.6803
Low:0.6803
Close:0.7048
52wk High:1.82
52wk Low:0.6300
Shares:10.13M
Float Shares:8.93M
Volume Ratio:0.49
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1141
EPS(LYR):3.19
ROE:-17.68%
ROA:-4.76%
PB:0.20
PE(LYR):0.22

Loading ...

Mar 18, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Dec 16, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 25, 2023

Major Issues Report

Form 8-K - Current report
Nov 23, 2023

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
Nov 16, 2023

Major Issues Report

Form 8-K - Current report
Nov 10, 2023

Major Issues Report

Form 8-K - Current report
Sep 28, 2023

Correspondence

Form CORRESP - Correspondence
Sep 18, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 08, 2023

Major Issues Report

Form 8-K - Current report
Aug 05, 2023

Correspondence

Form CORRESP - Correspondence
Aug 04, 2023

Major Issues Report

Form 8-K - Current report
Jul 31, 2023

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jul 19, 2023

Major Issues Report

Form 8-K - Current report
Jun 17, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Jun 05, 2023

Correspondence

Form CORRESP - Correspondence
May 30, 2023

Correspondence

Form CORRESP - Correspondence
May 19, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 12, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership